Upsher Smith logo

Media Contact:

Tara Marchese
Kovak-Likly Communications
203-762-8833
tmarchese@klcpr.com

"Loading the player…"
In the Epilepsy Comorbidities and Health (EPIC) Survey, 32.5% of people with epilepsy reported having comorbid depression vs. 25.6% of people without epilepsy. (Click image to view reference)
In the Epilepsy Comorbidities and Health (EPIC) Survey, 32.5% of people with epilepsy reported having comorbid depression vs. 25.6% of people without epilepsy. (Click image to view reference)

UPSHER-SMITH EXPANDS EPILOG.US WITH ADDITION OF EXPERT OPINION ON EPILEPSY & COMORBIDITIES

Updated Educational Website Unveiled at 64th Annual AAN Meeting

Maple Grove, MN – April 24, 2012 /PRNewswire/ — Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, http://www.Epilog.us, has been expanded to include thought-leader commentary on issues related to Epilepsy and Comorbidities.  The newly updated website will make its debut at the 64th Annual American Academy of Neurology Meeting in New Orleans on April 23 – 26, 2012, at the Upsher-Smith exhibit, booth number 128.

“Comorbidities create some of the most challenging issues for people with epilepsy and their families,” said Tom Burke, Chief Operating Officer, Upsher-Smith. “Upsher-Smith is pleased to add the latest thinking on this important patient management issue to Epilog.us, our educational website for healthcare professionals in the epilepsy community.”

Epilepsy and Comorbidities information available on Epilog.us include:

In addition to the updates on Epilog.us, Upsher-Smith also conducted an interactive quiz at the exhibit booth for all AAN attendees to explore their experience with epilepsy and comorbidities.

Epilog.us is a disease awareness website offering healthcare professionals who treat epilepsy current evidence-based scientific data, modern therapy issues, and expert insights provided by some of the field’s most respected clinicians. The site features regularly updated content including videos, white papers, podcasts, and interactive components addressing various epilepsy-related topics. With the expansion of Epilog.us, visitors to the site will now be able to access content previously highlighted including all multi-media and print components. Future topics to be featured on Epilog.us include: Practice Management, Aging with Epilepsy, and AED Pharmacodynamics.

Upsher-Smith’s Expanding CNS Pipeline
Upsher-Smith’s central nervous system (CNS) pipeline includes a number of investigational drug programs for various indications within epilepsy, including USL255, USL261, and USL260.

About Epilepsy
Epilepsy is a medical condition that produces seizures affecting a variety of mental and physical functions. Almost three million people in the U.S. have some form of epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1

About Upsher-Smith
Upsher-Smith Laboratories, Inc. is a privately held, U.S.-based company devoted to improving health and advancing wellness since 1919. Upsher-Smith demonstrates its commitment to meeting the healthcare needs of its customers by developing, producing and marketing consumer and prescription products. In addition to its strong heritage in generics, Upsher-Smith’s branded businesses focus on women’s health, dermatology and CNS therapeutic areas. For additional information, visit http://www.upsher-smith.com.

# # #


1 Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/. Accessed on March 1, 2012.